v3.25.4
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2025
Dec. 31, 2024
Operating expenses:        
Research and development $ 98,924 $ 94,520 $ 314,373 $ 267,266
General and administrative 15,438 19,782 58,975 57,061
Total operating expenses 114,362 114,302 373,348 324,327
Interest income, net (5,333) (4,590) (17,274) (17,844)
Other (income) expense, net 54 1,258 (1,383) 600
Loss before provision for income taxes (109,083) (110,970) (354,691) (307,083)
Provision for income taxes 1,552 152 3,059 308
Net loss $ (110,635) $ (111,122) $ (357,750) $ (307,391)
Net loss per common share - basic (in dollars per share) $ (0.61) $ (0.76) $ (2.04) $ (2.10)
Net loss per common share - diluted (in dollars per share) $ (0.61) $ (0.76) $ (2.04) $ (2.10)
Weighted-average common shares outstanding – basic (in shares) 181,513,386 146,922,338 175,414,491 146,560,414
Weighted-average common shares outstanding – diluted (in shares) 181,513,386 146,922,338 175,414,491 146,560,414

Source